Electronic Cigarettes as a Harm Reduction Strategy Among People With Opioid Use Disorder on Buprenorphine
Status: Recruiting
Location: See location...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
This project aims to investigate the impact of e-cigarette flavors and usage patterns on achieving harm-reduction milestones in a sample of cigarette smokers with opioid use disorder who are taking buprenorphine
Eligibility
Participation Requirements
Sex: All
Minimum Age: 21
Healthy Volunteers: f
View:
• Age ≥21 years
• Smoke ≥5 CPD for ≥1 year
• Daily CC smoker
• Willing to switch to EC
• Exhaled CO ≥6 ppm
• Diagnosed with OUD
• Stable on bupropion treatment
• In good physical and mental health
• Able to use a smartphone
• Willing to participate in all study components
Locations
United States
South Carolina
Addiction Medicine Center
RECRUITING
Greenville
Contact Information
Primary
Irene Pericot-Valverde, PhD
iperico@clemson.edu
(864)656-4467
Time Frame
Start Date: 2026-04-29
Estimated Completion Date: 2029-06-29
Participants
Target number of participants: 90
Treatments
Experimental: Sweet-Cooling EC + Counseling
Those randomized to the intervention group will be provided a free 12-week supply of sweet-cooling electronic cigarette (EC) liquid and five brief, individual counseling sessions, and asked to try to switch completely to EC.
Experimental: Sweet non-cooling EC + Counseling
Those randomized to the intervention group will be provided a free 12-week supply of sweet non-cooling electronic cigarette (EC) liquid and five brief, individual counseling sessions, and asked to try to switch completely to EC.
Active_comparator: Tobacco-flavored EC + Counseling
Those randomized to the intervention group will be provided a free 12-week supply of tobacco-flavored electronic cigarette (EC) liquid and five brief, individual counseling sessions, and asked to try to switch completely to EC.
Related Therapeutic Areas
Sponsors
Collaborators: National Institute on Drug Abuse (NIDA)
Leads: Prisma Health-Upstate